Literature DB >> 7987985

Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.

B Mitrovski1, J Pressacco, S Mandelbaum, C Erlichman.   

Abstract

The TS-inhibitory effects induced by a 24-h exposure to the folate-based TS inhibitors CB3717, C2-desamino analogs of CB3717 including D1694, and BW1843U89 were quantitated using the MGH-U1 human bladder carcinoma. The effects of D1694 on the time course of TS inhibition and on intracellular deoxyuridine monophosphate (dUMP) accumulation and deoxyuridine (dUrd) production were evaluated. D1694 and BW1843U89 were the most active TS inhibitors with IC50 values of 2.4 and 0.5 nM, respectively. The C2-desamino C2-methyl dideazafolates were 27-292 times more potent than the parent CB3717 as TS inhibitors. A methyl group at the C2 position of CB3717 had the most dramatic effect, whereas a thiazole substitution for a benzyl added a small benefit and N10 substitution had a limited impact on TS-inhibitory potency and clonogenic survival. There was a significant correlation between the IC50 values for TS inhibition and those for cytotoxic potency obtained for these drugs. LV and thymidine protected cells from these folate-based TS inhibitors. Intracellular dUMP levels following 24 h D1694 (IC50) exposure increased 7-fold. Levels of dUrd effluxing into the media increased up to 4.5 microM following a 24-h exposure to D1694 (IC90). We conclude that (a) C2-desamino C2-methyl dideazafolates are potent TS inhibitors, (b) TS inhibition requires prolonged exposure with these folate TS inhibitors, (c) survival is correlated with inhibition of TS for the folate-based TS inhibitors and (d) the biochemical consequences of TS inhibition include increased dUMP and dUrd levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987985     DOI: 10.1007/BF00686631

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

1.  Comparison of in vitro drug sensitivity by inhibition of tritium release from [5-3H]-2'-deoxyuridine and a clonogenic assay.

Authors:  C Aschele; A Romanini; A Nicolin; R Rosso; A Sobrero
Journal:  Anticancer Res       Date:  1990 May-Jun       Impact factor: 2.480

2.  An isotopic assay for thymidylate synthetase.

Authors:  D Roberts
Journal:  Biochemistry       Date:  1966-11       Impact factor: 3.162

3.  Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency.

Authors:  T R Jones; T J Thornton; A Flinn; A L Jackman; D R Newell; A H Calvert
Journal:  J Med Chem       Date:  1989-04       Impact factor: 7.446

4.  Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.

Authors:  C Erlichman; B Mitrovski
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717.

Authors:  A L Jackman; G A Taylor; A H Calvert; K R Harrap
Journal:  Biochem Pharmacol       Date:  1984-10-15       Impact factor: 5.858

6.  Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro.

Authors:  J C Yalowich; T I Kalman
Journal:  Biochem Pharmacol       Date:  1985-07-01       Impact factor: 5.858

7.  Quinazoline antifolates inhibiting thymidylate synthase: computer modelling of the N10 substituent.

Authors:  T R Jones; R F Betteridge; S Neidle; A L Jackman; A H Calvert
Journal:  Anticancer Drug Des       Date:  1989-03

8.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.

Authors:  A L Jackman; G A Taylor; W Gibson; R Kimbell; M Brown; A H Calvert; I R Judson; L R Hughes
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

9.  Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.

Authors:  D S Duch; S Banks; I K Dev; S H Dickerson; R Ferone; L S Heath; J Humphreys; V Knick; W Pendergast; S Singer
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

10.  The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).

Authors:  A L Jackman; D R Newell; W Gibson; D I Jodrell; G A Taylor; J A Bishop; L R Hughes; A H Calvert
Journal:  Biochem Pharmacol       Date:  1991-10-24       Impact factor: 5.858

View more
  8 in total

1.  MLH1 deficiency enhances radiosensitization with 5-fluorodeoxyuridine by increasing DNA mismatches.

Authors:  Sheryl A Flanagan; Christina M Krokosky; Sudha Mannava; Mikhail A Nikiforov; Donna S Shewach
Journal:  Mol Pharmacol       Date:  2008-06-05       Impact factor: 4.436

2.  Fragment-based discovery of novel thymidylate synthase leads by NMR screening and group epitope mapping.

Authors:  Darren W Begley; Suxin Zheng; Gabriele Varani
Journal:  Chem Biol Drug Des       Date:  2010-07-05       Impact factor: 2.817

Review 3.  Spliceosomal snRNA modifications and their function.

Authors:  John Karijolich; Yi-Tao Yu
Journal:  RNA Biol       Date:  2010-03-14       Impact factor: 4.652

4.  Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression.

Authors:  Alessio Ligabue; Gaetano Marverti; Ursula Liebl; Hannu Myllykallio
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

5.  Thiothymidine combined with UVA as a potential novel therapy for bladder cancer.

Authors:  S W Pridgeon; R Heer; G A Taylor; D R Newell; K O'Toole; M Robinson; Y-Z Xu; P Karran; A V Boddy
Journal:  Br J Cancer       Date:  2011-05-24       Impact factor: 7.640

6.  5-Fluorouracil Treatment Alters the Efficiency of Translational Recoding.

Authors:  Junhui Ge; John Karijolich; Yingzhen Zhai; Jianming Zheng; Yi-Tao Yu
Journal:  Genes (Basel)       Date:  2017-10-31       Impact factor: 4.096

Review 7.  Stress Granules in the Anti-Cancer Medications Mechanism of Action: A Systematic Scoping Review.

Authors:  Mohammad Reza Asadi; Marziyeh Sadat Moslehian; Hani Sabaie; Marziye Poornabi; Elham Ghasemi; Mehdi Hassani; Bashdar Mahmud Hussen; Mohammad Taheri; Maryam Rezazadeh
Journal:  Front Oncol       Date:  2021-12-24       Impact factor: 6.244

8.  5-fu metabolism in cancer and orally-administrable 5-fu drugs.

Authors:  Koh Miura; Makoto Kinouchi; Kazuyuki Ishida; Wataru Fujibuchi; Takeshi Naitoh; Hitoshi Ogawa; Toshinori Ando; Nobuki Yazaki; Kazuhiro Watanabe; Sho Haneda; Chikashi Shibata; Iwao Sasaki
Journal:  Cancers (Basel)       Date:  2010-09-17       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.